Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by COURTRIGHT, P.
Right arrow Articles by LEWALLEN, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by COURTRIGHT, P.
Right arrow Articles by LEWALLEN, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1994 Oxford University Press

other

Multidrug Therapy and Eye Disease in Leprosy: A Cross-Sectional Study in the People's Republic of China

PAUL COURTRIGHT*,**, LU-FANG HU{dagger}, HUAN-YING LI{ddagger} and SUSAN LEWALLEN**

* International Centre for Eye Health Bath Street, London, EC1V 9EL, UK
** International Eye Foundation PO Box 2273, Blantyre, Malawi
{dagger} Sichuan Provincial Institute of Dermatology 12 Si Dao Jie, Chengdu, Sichuan Province, PR China
{ddagger} Beijing Tropical Medicine Research Institute, Friendsip Hospital 95 Yun An Lu, Beijing, PR China

BackgroundFactors associated with leprosy-related eye disease in a multidrug therapy (MDT) treated population in China were assessed to determine if status prior to inclusion in the MDT programme (newly diagnosed leprosy patient or leprosy patient on prior dapsone monotherapy) contributed to the prevalence of ocular pathology.

MethodsTrained Leprosy paramedical workers in Sichuan Province examined 974 leprosy patients in a standardized fashion. Univariate analyses and multiple logistic regression were used to assess the contribution of demographic and clinical parameters to leprosy-related eye disease.

ResultsIn both groups (prior dapsone and new MDT) leprosy-related eye disease was associated with a longer distance to leprosy health worker or health centre. Among patients with a history of prior dapsone monotherapy, age and duration on dapsone monotherapy were elso associated with leprosy-related ocular morbidity. Among newly diagnosed leprosy patients the prevalence of ocular morbidity remained between 8% and 11% regardless of when the patient started MDT.

ConclusionsOur findings suggest that, even when case detection is good, ocular pathology will still occur in MDT treated leprosy patients. There remains an important role for health workers in the prevention of ocular morbidity. Our data also demonstrated that pooling of results from all patients (newly diagnosed and on prior dapsone monotherapy) in a leprosy control programme will likely give rise to inadequate estimates of risk of ocular disease due to variable clinical disease histories in these groups.

Received 1 January 1994


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Br. J. Ophthalmol.Home page
E Daniel, T J ffytche, P S S Sundar Rao, J H Kempen, M Diener-West, and P Courtright
Incidence of ocular morbidity among multibacillary leprosy patients during a 2 year course of multidrug therapy
Br. J. Ophthalmol., May 1, 2006; 90(5): 568 - 573.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
C Mpyet and A W Solomon
Prevalence and causes of blindness and low vision in leprosy villages of north eastern Nigeria
Br. J. Ophthalmol., April 1, 2005; 89(4): 417 - 419.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.